Black Diamond Therapeutics
Price & Volume
Stats
See moreOpen | $2.82 |
Previous Close | $2.83 |
Day Range | $2.81-$2.87 |
52W Range | $1.77-$4.94 |
Market Cap | $168.4M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $70M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $70M |
Diluted EPS | -$0.77 |
News
See moreYahoo Finance • 3 months ago
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
Yahoo Finance • 5 months ago
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Yahoo Finance • 5 months ago
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Yahoo Finance • 6 months ago
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
About
CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Address | 245 First Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 21 |